PURPOSE To determine the sensitivity and specificity of genetic testing criteria for the
detection of germline pathogenic variants in women with breast cancer. MATERIALS AND …

Purpose An estimated 10% of breast and ovarian cancers result from hereditary causes.
Current testing guidelines for germ line susceptibility genes in patients with breast …

Purpose Testing for germline mutations in BRCA1/2 is standard for select patients with
breast cancer to guide clinical management. Next-generation sequencing (NGS) allows …

Importance The increasing use of germline genetic testing may have unintended
consequences on treatment. Little is known about how women with pathogenic variants in …

Importance Germline pathogenic variants inBRCA1andBRCA2predispose to an increased
lifetime risk of breast cancer. However, the relevance of germline variants in other genes …

Genetic testing for germline mutations in breast cancer predisposition genes can potentially
identify individuals at a high risk of developing breast and/or ovarian cancer. There is a …

BACKGROUND Next‐generation sequencing (NGS) allows for simultaneous sequencing of
multiple cancer susceptibility genes and, for an individual, may be more efficient and less …

PURPOSE To develop recommendations for germline mutation testing for patients with
breast cancer. METHODS An ASCO–Society of Surgical Oncology (SSO) panel convened to …

Purpose Gene panel sequencing is revolutionizing germline risk assessment for hereditary
breast cancer. Despite scant evidence supporting the role of many of these genes in breast …

Purpose Many women with an elevated risk of hereditary breast and ovarian cancer have
previously tested negative for pathogenic mutations in BRCA1 and BRCA2. Among them, a …